April 3, 2019 07:00 AM EDTUpdated May 30, 11:22 AM
Pharma

Ed­i­tas and Blue­Rock join forces — and plat­form tech­nolo­gies — on a new wave of en­gi­neered cell ther­a­pies

John Carroll

Editor & Founder

Two promi­nent Boston-based biotechs are ty­ing their plat­form tech­nolo­gies to­geth­er to see how they can give each oth­er a boost to their re­spec­tive pipelines. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times